
Rasagil0.5 mg
Healthcare Pharmaceuticals Ltd.
Rasagiline is a selective irreversible inhibitor of monoamine oxidase type B (MAO-B), approved for the treatment of idiopathic Parkinson's disease (PD).
Rasagiline is a selective irreversible inhibitor of monoamine oxidase type B (MAO-B), approved for the treatment of idiopathic Parkinson's disease (PD).
Rasagiline has been studied for possible disease-modifying (neuroprotective) effects in Parkinson's disease, but this benefit has not been definitively established, and it is not an approved indication.
| Indication | Dose |
|---|---|
| Monotherapy (early Parkinson's disease) | 1 mg orally once daily |
| Adjunct to levodopa (advanced Parkinson's disease) | Initiate at 0.5 mg once daily; may increase to 1 mg once daily based on response and tolerability |
Rasagiline may be taken with or without food, at approximately the same time each day. A reduction in the levodopa dose may be considered in patients receiving combination therapy who develop dopaminergic side effects (e.g., dyskinesia).
Patients should promptly report any unusual behavioral changes, fainting spells, or skin lesions to their physician.
Rasagiline is contraindicated in:
An adequate washout period (at least 14 days) is required between stopping Rasagiline and starting any of these contraindicated agents, and vice versa (5 weeks for fluoxetine).
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.